The training of psychotherapists has begun for a clinical trial that will examine 5-MeO-DMT assisted psychotherapy in treatment-resistant depression (TRD).
The application is for a clinical trial that intends to test the psilocybin extract for bioavailability and tolerability on 20 healthy volunteers.
Results from a new study have demonstrated that 10mg or 25mg doses of psilocybin have no long- or short-term detrimental effects in healthy individuals.
Mydecine Innovations Group recently signed a five-year agreement with Johns Hopkins University School of Medicine that will advance research on novel psychedelic therapy.
Return Health is exploring psychedelic derivatives for the treatment of dementia.
MindMed is expected to begin enrolling patients immediately into its proof-of-concept exploratory trial for the use of LSD to treat adult ADHD.
The new guidance from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) stating that the use of real-world data from clinical trials could help with...
Braxia Scientific has dosed the first patients in its multi-dose psilocybin clinical trial exploring the compound’s efficacy for treatment-resistant depression (TRD).
Wesana Health and MAPS have announced the receipt of a commercial viability analysis conducted by the Boston Consulting Group (BCG) which will bring the parties closer...
Positive outcomes for the use of psilocybin therapy in conjunction with SSRIs have been reported from COMPASS Pathways’ Phase IIb trial.